BACKGROUND: Human immunodeficiency virus type 1(HIV-1) infects and activates innate immune cells in the brain resulting in inflammation and neuronal death with accompanying neurological deficits. Induction of inflammasomes causes cleavage and release of IL-1β and IL-18, representing pathogenic processes that underlie inflammatory diseases although their contribution HIV-associated brain disease is unknown. RESULTS: Investigation of inflammasome-associated genes revealed that IL-1β, IL-18 and caspase-1 were induced in brains of HIV-infected persons and detected in brain microglial cells. HIV-1 infection induced pro-IL-1β in human microglia at 4 hr post-infection with peak IL-1β release at 24 hr, which was accompanied by intracellular ASC translocation and caspase-1 activation. HIV-dependent release of IL-1β from a human macrophage cell line, THP-1, was inhibited by NLRP3 deficiency and high extracellular [K+]. Exposure of microglia to HIV-1 gp120 caused IL-1β production and similarly, HIV-1 envelope pseudotyped viral particles induced IL-1β release, unlike VSV-G pseudotyped particles. Infection of cultured feline macrophages by the related lentivirus, feline immunodeficiency virus (FIV), also resulted in the prompt induction of IL-1β. In vivo FIV infection activated multiple inflammasome-associated genes in microglia, which was accompanied by neuronal loss in cerebral cortex and neurological deficits. Multivariate analyses of data from FIV-infected and uninfected animals disclosed that IL-1β, NLRP3 and caspase-1 expression in cerebral cortex represented key molecular determinants of neurological deficits. CONCLUSIONS: NLRP3 inflammasome activation was an early and integral aspect of lentivirus infection of microglia, which was associated with lentivirus-induced brain disease. Inflammasome activation in the brain might represent a potential target for therapeutic interventions in HIV/AIDS.
BACKGROUND:Humanimmunodeficiency virus type 1(HIV-1) infects and activates innate immune cells in the brain resulting in inflammation and neuronal death with accompanying neurological deficits. Induction of inflammasomes causes cleavage and release of IL-1β and IL-18, representing pathogenic processes that underlie inflammatory diseases although their contribution HIV-associated brain disease is unknown. RESULTS: Investigation of inflammasome-associated genes revealed that IL-1β, IL-18 and caspase-1 were induced in brains of HIV-infectedpersons and detected in brain microglial cells. HIV-1 infection induced pro-IL-1β in human microglia at 4 hr post-infection with peak IL-1β release at 24 hr, which was accompanied by intracellular ASC translocation and caspase-1 activation. HIV-dependent release of IL-1β from a human macrophage cell line, THP-1, was inhibited by NLRP3 deficiency and high extracellular [K+]. Exposure of microglia to HIV-1gp120 caused IL-1β production and similarly, HIV-1 envelope pseudotyped viral particles induced IL-1β release, unlike VSV-G pseudotyped particles. Infection of cultured feline macrophages by the related lentivirus, feline immunodeficiency virus (FIV), also resulted in the prompt induction of IL-1β. In vivo FIV infection activated multiple inflammasome-associated genes in microglia, which was accompanied by neuronal loss in cerebral cortex and neurological deficits. Multivariate analyses of data from FIV-infected and uninfected animals disclosed that IL-1β, NLRP3 and caspase-1 expression in cerebral cortex represented key molecular determinants of neurological deficits. CONCLUSIONS:NLRP3 inflammasome activation was an early and integral aspect of lentivirus infection of microglia, which was associated with lentivirus-induced brain disease. Inflammasome activation in the brain might represent a potential target for therapeutic interventions in HIV/AIDS.
Authors: Sanjeev Mariathasan; David S Weiss; Kim Newton; Jacqueline McBride; Karen O'Rourke; Meron Roose-Girma; Wyne P Lee; Yvette Weinrauch; Denise M Monack; Vishva M Dixit Journal: Nature Date: 2006-01-11 Impact factor: 49.962
Authors: M Christine Zink; Victoria A Laast; Kristi L Helke; Angela K Brice; Sheila A Barber; Janice E Clements; Joseph L Mankowski Journal: Curr HIV Res Date: 2006-07 Impact factor: 1.581
Authors: Juan Pablo de Rivero Vaccari; George Lotocki; Alex E Marcillo; W Dalton Dietrich; Robert W Keane Journal: J Neurosci Date: 2008-03-26 Impact factor: 6.167
Authors: Amina A Negash; Hilario J Ramos; Nanette Crochet; Daryl T Y Lau; Brian Doehle; Neven Papic; Don A Delker; Juandy Jo; Antonio Bertoletti; Curt H Hagedorn; Michael Gale Journal: PLoS Pathog Date: 2013-04-25 Impact factor: 6.823
Authors: Michael J Peluso; Victor Valcour; Nittaya Phanuphak; Jintanat Ananworanich; James L K Fletcher; Thep Chalermchai; Shelly J Krebs; Merlin L Robb; Joanna Hellmuth; Magnus Gisslén; Henrik Zetterberg; Serena Spudich Journal: AIDS Date: 2017-01-14 Impact factor: 4.177
Authors: Ernest T Chivero; Ming-Lei Guo; Palsamy Periyasamy; Ke Liao; Shannon E Callen; Shilpa Buch Journal: J Neurosci Date: 2017-03-07 Impact factor: 6.167
Authors: Weston C Roda; Michael Y Li; Michael S Akinwumi; Eugene L Asahchop; Benjamin B Gelman; Kenneth W Witwer; Christopher Power Journal: J Neurovirol Date: 2017-05-16 Impact factor: 2.643
Authors: Jerel Adam Fields; Elisabeth Serger; Sofia Campos; Ajit S Divakaruni; Changyoun Kim; Kendall Smith; Margarita Trejo; Anthony Adame; Brian Spencer; Edward Rockenstein; Anne N Murphy; Ronald J Ellis; Scott Letendre; Igor Grant; Eliezer Masliah Journal: Neurobiol Dis Date: 2015-11-22 Impact factor: 5.996
Authors: Lee A Campbell; Christopher T Richie; Yajun Zhang; Emily J Heathward; Lamarque M Coke; Emily Y Park; Brandon K Harvey Journal: FEBS J Date: 2017-11-08 Impact factor: 5.542